Back to User profile » Dr Sylvie Dejager
Papers published by Dr Sylvie Dejager:
Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database
Detournay B, Halimi S, Robert J, Deschaseaux C, Dejager S
Vascular Health and Risk Management 2015, 11:417-425
Published Date: 17 July 2015
Potential glycemic overtreatment in patients ≥75 years with type 2 diabetes mellitus and renal disease: experience from the observational OREDIA study
Penfornis A, Fiquet B, Blicklé JF, Dejager S
Diabetes, Metabolic Syndrome and Obesity 2015, 8:303-313
Published Date: 3 July 2015
Physical activity in patients with type 2 diabetes and hypertension – insights into motivations and barriers from the MOBILE study
Duclos M, Dejager S, Postel-Vinay N, di Nicola S, Quéré S, Fiquet B
Vascular Health and Risk Management 2015, 11:361-371
Published Date: 29 June 2015
How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study
Penfornis A, Blicklé JF, Fiquet B, Quéré S, Dejager S
Vascular Health and Risk Management 2014, 10:341-352
Published Date: 13 June 2014
Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan
Schweizer A, Halimi S, Dejager S
Vascular Health and Risk Management 2014, 10:15-24
Published Date: 24 December 2013
Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
Dejager S, Schweizer A, Foley JE
Vascular Health and Risk Management 2012, 8:339-348
Published Date: 18 May 2012
Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
Anja Schweizer, Sylvie Dejager, James E Foley, et al
Vascular Health and Risk Management 2011, 7:49-57
Published Date: 4 February 2011